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Recombinant adeno-associated viruses (rAAVs) hold enormous potential for human gene therapy. Despite the well-established
safety and efficacy of rAAVs for in vivo gene transfer, there is still little information concerning the fate of vectors in blood fol-
lowing systemic delivery. We screened for serum proteins interacting with different AAV serotypes in humans, macaques, dogs,
and mice. We report that serotypes rAAV-1, -5, and -6 but not serotypes rAAV-2, -7, -8, -9, and -10 interact in human sera with
galectin 3 binding protein (hu-G3BP), a soluble scavenger receptor. Among the three serotypes, rAAV-6 has the most important
capacities for binding to G3BP. rAAV-6 also bound G3BP in dog sera but not in macaque and mouse sera. In mice, rAAV-6 inter-
acted with another protein of the innate immune system, C-reactive protein (CRP). Furthermore, interaction of hu-G3BP with
rAAV-6 led to the formation of aggregates and hampered transduction when the two were codelivered into the mouse. Based on
these data, we propose that species-specific interactions of AAVs with blood proteins may differentially impact vector distribu-
tion and efficacy in different animal models.
The recombinant adeno-associated vector (rAAV) platform,derived from a nonpathogenic dependovirus, has many attri-
butes suitable for in vivo gene transfer: rAAV vectors are capable of
transducing a wide range of cell types, including dividing and
nondividing cells; rAAV genomes persist as episomal chromatin
in the nucleus of transduced cells (38); and stable, persistent ex-
pression has been reported for many transgenes in different tissues
and species (6, 12, 36, 39). rAAVs have proven to be efficient in
preclinical studies in animal models (16, 28), and results from
clinical trials are promising (7, 47).
In the case of systemic diseases, clinical relevance requires
widespread distribution of the vector in order to target entire or-
gans. This is particularly true for myopathies, where all striated
muscles of the skeletal musculature and, frequently, cardiac mus-
cles have to be treated. In this case, vascular delivery would be the
optimal route for rAAV administration. Intravascular injection of
a number of rAAV serotypes has proven efficient in murine mod-
els of muscular dystrophies (11, 17, 18, 34, 35). However, trans-
lating this approach to large animal models and humans is still
challenging. Acquired immunity and neutralizing antibodies
present in a large fraction of the human population might obvi-
ously be restrictive for rAAV gene delivery (5, 20, 27, 29, 30).
Moreover, recent studies have demonstrated that serum might
also contain other factors neutralizing rAAV vectors (40), indicat-
ing that detailed characterization of rAAV’s molecular interac-
tions in the bloodstream is obviously important in order to im-
prove vector efficacy.
We looked for serum proteins, other than immunoglobulins,
which could interact with rAAVs in the bloodstreams of different
species. By using a multidisciplinary approach involving pro-
teomics, binding assays, electron microscopy (EM), and in vivo
studies, we demonstrated that rAAV-6 interacted specifically with
C-reactive protein (CRP) in mice and galectin 3 binding protein
(G3BP) in humans and dogs. Interestingly, CRP belongs to the
short pentraxins, whose main functions are to recognize a variety
of pathogenic agents (2), and G3BP contains a scavenger receptor
cysteine-rich (SRCR) domain, which plays an important role in
uptake and clearance of weakened components, such as modified
host molecules and apoptotic cells (26, 37). We found that in
human serum human G3BP (hu-G3BP) was able to aggregate and
precipitate rAAV-6. More importantly, this protein was able to
reduce rAAV-6 transduction efficiency when administered intra-
muscularly or intravenously in the mouse. Taken together, these
results demonstrate that rAAV vectors can interact with serum
proteins in a species-specific manner and that this phenomenon
should be taken into consideration regarding vector distribution/
efficacy in different animal models.
MATERIALS AND METHODS
rAAV production. Pseudotyped rAAV vectors were generated by packag-
ing AAV2-based recombinant genomes into rAAV-1, -2, -5, -6, -8, -9, and
-10 capsids using previously described methods. Adenovirus-free vectors
were generated either by using a three-plasmid transfection of HEK293
cells (rAAV-1, -2, -5, -6, -9, and -10) (13, 50) or by double infection of Sf9
cells (rAAV-6, -8, and -9) (44). rAAV vectors were purified either by
affinity chromatography using AVB Sepharose HP (IA beads) (GE
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Healthcare Life Sciences, Piscataway, NJ) (44) or by a standard procedure
including two cycles of cesium chloride or iodixanol gradient centrifuga-
tion (22). The number of viral genomes (vg) was estimated by quantitative
PCR (qPCR) of extracted vector DNA. The numbers of vector physical
particles (pp) were estimated either by an enzyme-linked immunosorbent
assay (ELISA)-based method or by quantification of VP3 protein after
SDS-PAGE analysis of samples stained with Coomassie blue G250 with
bovine serum albumin (BSA) as a standard. Contents of full capsids were
very similar for the different serotypes used in the study: the ratio of viral
genomes to physical particles varied from 1/3 to 1/10.
Animals. Healthy, 4-week-old C57BL/6 mice were used in the study.
All the procedures involving animals were performed according to the
guidelines of the Animal Ethical Committee of our institute. All experi-
ments were performed at least in duplicate and some in triplicate, with at
least three mice used for each condition. For systemic delivery, 6  10E11
vg of rAAV-6 or 1  10E11 vg of rAAV-9 (prepared by triple transfection
of 293 cells and purified by ultracentrifugation on iodixanol) coding for
the murine secreted embryonic alkaline phosphatase (MuSEAP) (49) un-
der the cytomegalovirus (CMV) promoter were injected into the lateral
tail vein. For intramuscular delivery, the following quantities of vectors
were injected into the left tibialis anterior (TA) muscle after anesthesia by
intraperitoneal injection of ketamine (100 mg/kg of body weight; Virbac)
and xylazine (10 mg/kg; Rompun): 5  10E9 vg of rAAV-6, rAAV-7, and
rAAV-1 or 1  10E9 vg of rAAV-9 coding for MuSEAP. Vectors and
hu-G3BP at the physiological concentration were incubated for 1 h at
ambient temperature before injections. The final volume was adjusted to
120 l or 20 l with phosphate-buffered saline (PBS) for intravenous and
intramuscular injections, respectively. Mice were sacrificed 2 weeks after
injection, and serum levels of MuSEAP were evaluated by chemilumines-
cence reporter assay (Tropix, Bedford MA).
Sera. Commercially available human serum (Sigma, St. Louis, MO) or
serum samples from healthy human adults obtained in accordance with
regulatory guidelines were used in the experiments. Canine sera were
obtained from two healthy golden retriever dogs of 6 and 9 months of age
(Ecole Nationale Vétérinaire d’Alfort). Macaque (Macaca fascicularis)
sera were obtained from the Ecole Nationale Vétérinaire de Nantes. Sera
used in this study were assessed for the presence of antibodies according to
the method in reference 5 and were seronegative for the respective AAV
serotypes. Before coprecipitation assays, sera were processed by ultracen-
trifugation at 230,000  g for 2 h (Beckman 100 ultracentrifuge; TLA
100.4 rotor).
Coprecipitation experiments. Serum proteins interacting with rAAV
were coprecipitated from processed serum by ultracentrifugation at
40,000  g for 2 h at room temperature (Beckman 100 ultracentrifuge;
TLA 100.4 rotor). Pellets were washed with 4.7 ml of PBS and reprecipi-
tated under the same conditions. The resulting precipitates were resus-
FIG 1 Proteomic analysis of human serum proteins interacting with rAAV-6. (A and B) Human serum proteins recovered by coimmunoprecipitation with
AVB-Sepharose immunoaffinity beads in the presence (A) or absence (B) of rAAV-6 (10E12 physical particles) and analyzed by 2-DE. In the presence of rAAV-6,
in addition to the AAV capsid proteins, VP1, VP2, and VP3, a number of protein spots with similar molecular masses (about 90 kDa) and isoelectric points (5.1
to 5.2) were reproducibly detected (5 experiments), but they were not seen in the absence of rAAV-6. MALDI-TOF analysis identified these spots as human
galectin 3 binding protein (hu-G3BP). Identification of G3BP was confirmed by Western blot analysis. (C) Coomassie blue staining of SDS-PAGE gel. (D)
Corresponding polyvinylidene difluoride (PVDF) membrane probed with a goat polyclonal antibody against hu-G3BP (1:1,000; R&D Systems). Lanes 1 and 2,
protein extracts from human serum recovered via AVB immunoaffinity beads with rAAV-6 or beads alone, respectively. Lane 3, 100 ng of recombinant
nonglycosylated G3BP (65-kDa molecular mass). The AAV capsid proteins, VP1, VP2, and VP3, as well as serum hu-G3BP (around 90 kDa in molecular mass),
were found in lane 1. Two faint bands of about 70 kDa and 26 kDa, corresponding to N-terminal and C-terminal fragments, were generated by proteolytic
cleavage of hu-G3BP (26, 42). In lane 2, empty beads did not retain hu-G3BP, although some proteins could be recovered depending on washing stringency.
Numbers to the left of each panel are molecular masses in kilodaltons.
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pended in 200 l of PBS, and proteins were precipitated with 2 volumes of
cold acetone. For two-dimensional gel electrophoresis (2-DE), proteins
were dissolved in 180 l of rehydration buffer (7 M urea, 2 M thiourea, 1%
[vol/vol] Triton X-100, 1% [wt/vol] amidosulfobetaine-14 [ASB-14], 2%
[wt/vol] 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfon-
ate [CHAPS], and 20 mM dithiothreitol [DTT]).
Coimmunoprecipitation. Coimmunoprecipitation of serum pro-
teins was performed with rAAV vectors immobilized on AAV capsid-
specific immunoaffinity beads (AVB-Sepharose beads; GE Healthcare Life
Sciences, Piscataway, NJ)) (4). Immobilized rAAV vectors (5 l of AVB
Sepharose/1  10E12 vector particles) were incubated with 400 l of
serum for 1 h. Beads were collected by centrifugation and washed four
times with 1 PBS. The immunoprecipitate was solubilized in the appro-
priate buffer for further analysis by one-dimensional (1-D) or 2-D elec-
trophoresis.
Low-speed centrifugation. Putative aggregate formation with rAAV-6,
-1, and -9 was assessed by low-speed centrifugation. The respective rAAV
(2  10E11 physical particles alone or with hu-G3BP at 20 g/ml) was
incubated in 80 l of PBS containing 20 g/ml of hu-G3BP for 1 h and
centrifuged at 2,000  g for 10 min, and then the supernatant (70 l) was
carefully discarded. Ten-microliter aliquots from the supernatant and
precipitate were analyzed by SDS-PAGE. Repartition of rAAV in the two
compartments was estimated by Coomassie blue staining of viral proteins.
Serum depletion of G3BP. Human serum was depleted of G3BP by
incubation with anti-G3BP antibodies bound to magnetic beads for 2 h at
room temperature. Coupling of anti-G3BP SP-2 mouse monoclonal IgG1
(MediaPharma, Italy) to activated magnetic beads (Dynabeads M-450
Tosylactivated; Invitrogen, Oslo, Norway) was performed according to
the manufacturer’s instructions. Five micrograms of antibody was used in
a reaction mixture with 25 l of magnetic beads.
G3BP purification from human serum. Human G3BP was purified
with anti-G3BP antibodies bound to the magnetic beads. The beads were
washed extensively with PBS supplemented with 0.5% Triton X-100, fol-
lowed by PBS. The adsorbed proteins were eluted in 200 mM Tris buffer,
pH 9.5. Typically, 2.5 g of hu-G3BP per 1 ml of serum was obtained.
2-DE and protein identification. Two-dimensional gel electrophoresis
(2-DE) analysis, Coomassie blue staining, and identification of proteins
separated by 2-DE were performed as previously described (10). Tryptic
monoisotopic peptide masses were searched by using Aldente software (ver-
sion 11 February 2008) in the UniProtKB/Swiss-Prot database (release 56.9 of
3 March 2009) or by Protein Prospector (http://prospector.ucsf.edu) in the
NCBI (25 November 2008) and UniProtKB (10 June 2008) databases with the
FIG 2 Proteomic analysis of dog serum proteins interacting with rAAV-6. (A and B) Dog serum proteins recovered by ultracentrifugation in the presence (A)
or absence (B) of rAAV-6 (10E12 physical particles) and analyzed by 2-DE. In the presence of rAAV-6, in addition to the AAV capsid proteins, VP1, VP2, and
VP3, a number of protein spots with similar molecular masses (about 85 kDa) and isoelectric points (5.0 to 5.2) were reproducibly detected (4 experiments), but
they were not seen in the absence of rAAV-6. MALDI-TOF analysis identified these spots as dog galectin 3 binding protein (G3BP). Identification of G3BP was
confirmed by coimmunoprecipitation with AVB-Sepharose immunoaffinity beads followed by Western blot analysis. (C) Coomassie blue staining of SDS-PAGE
gel. (D) Corresponding polyvinylidene difluoride (PVDF) membrane probed with a rabbit polyclonal antibody against the rat protein homolog of G3BP, CyCAP
(1:500; Immuno-Biological Laboratories Co., Ltd., Minneapolis, MN). Lanes 1 and 2, protein extracts from human serum recovered via AVB immunoaffinity
beads with rAAV-6 or beads alone, respectively. The AAV capsid proteins, VP1, VP2, and VP3, as well as serum dog G3BP (around 80 kDa in molecular mass),
were found in lane 1. In lane 2, empty beads did not retain hu-G3BP, although some proteins could be recovered depending on washing stringency. Multiple
bands revealed by the antibody could be due to the variable pattern of dog G3BP glycosylation. Numbers to the left of each panel are molecular masses in
kilodaltons.
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following parameters: human/mouse/dog species, one missed cleavage site,
and mass tolerance setting of 20 ppm. Partial chemical modification such as
oxidation of methionine was taken into consideration for the queries. High-
est-confidence identifications have statistically significant search scores, are
consistent with the gel region from which the protein was excised (molecular
weight [MW] and pI), and account for the extent of sequence coverage and
the number of peptides matched.
Western blot analysis. Protein samples were separated by electropho-
resis onto a 4 to 12% gradient SDS-polyacrylamide gel and transferred
onto a PVDF-Plus polyvinylidene difluoride (PVDF) membrane (Milli-
pore). The following primary antibodies were used: goat polyclonal anti-
body to hu-G3BP (1:1,000; R&D Systems); goat polyclonal antibody to
mouse CRP (1:1,000; R&D Systems), mouse monoclonal antibody to hu-
man CRP (1:250; R&D Systems), and rabbit polyclonal antibody to the rat
protein homolog of G3BP, CyCAP (1:500; Immuno-Biological Laborato-
ries Co., Ltd., Minneapolis, MN) followed by corresponding IRDye-
800CW- or IRDye-600CW-conjugated antibodies (1:10,000) according
to the manufacturer’s instructions (Li-Cor Bioscience). Infrared fluores-
cence of the secondary antibodies was read on an Odyssey imaging system.
Estimation of rAAV-6/hu-G3BP ratios in the complexes. The rAAV-
6/hu-G3BP ratio was estimated by quantifying the amount of rAAV-6 and
hu-G3BP in coprecipitates. Amounts of rAAV were evaluated by estimat-
ing VP3 protein content on corresponding SDS-PAGE gels after Coomas-
sie blue staining, using the known quantity of rAAV-6 as a standard, while
G3BP was estimated by Western blot analysis using known quantities of
hu-G3BP (GenWayBio) as a standard.
Transmission electron microscopy. Aliquots of vectors (10E11 phys-
ical particles) were incubated in the presence of either (i) 10 g/ml of BSA,
(ii) BSA plus 1 g/ml of hu-G3BP, or (iii) BSA plus 10 g/ml of hu-G3BP
for 1 h. Vector particles (1  10E11 physical particles) or the mixtures
with hu-G3BP were applied to Formvar-coated copper grids and then
negatively stained with 3% uranyl acetate. Images were obtained with a
JEOL JEM-100S transmission electron microscope (magnification from
50,000 to 100,000).
SPRi. Experiments were performed using a surface plasmon reso-
nance imagery (SPRi) machine from Genoptics. Vectors (0.2 l of 1012 to
1013 pp/ml) were immobilized on a glass prism as described before (33). A
dose-dependent binding study was performed using several dilutions of
hu-G3BP (10 nM, 20 nM, and 40 nM) with PBS as a running buffer, and
then the rAAV surface was regenerated by injection of 100 l of 25 mM
NaOH (8). In order to determine the kinetic constants, SPRi data were
analyzed with BiaEvaluation software (Biacore) by using a 1:1 Langmuir
binding model. Data from four different concentrations of hu-G3BP were
used for the analysis, and the experiment was repeated three times.
RESULTS
rAAV-6 interacts with G3BP in human and dog sera but not in
macaque serum. Association of serum proteins with purified
rAAV-6 was tested in human serum samples from AAV-6 anti-
body-seronegative individuals. Proteins interacting with vectors
were recovered via rAAV-6 immobilized on immunoaffinity
AVB-Sepharose beads followed by 2-D gel analysis. In a reproduc-
ible manner, 2-D gels revealed numerous specific spots with sim-
ilar molecular masses (about 90 kDa) and isoelectric points (5.1 to
5.2) when incubated in the presence of AAV vector (Fig. 1A and
B). These spots were identified as human galectin 3 binding pro-
tein (hu-G3BP) by matrix-assisted laser desorption ionization–
time of flight (MALDI-TOF) analysis (12/35 peptide matching
[33%]; 21% of coverage; MOWSE score, 1.58  10E6). In addi-
tion to G3BP, a number of other spots were observed on the 2-D
gels, and the most abundant of these spots were identified by mass
spectrometry as albumin, heavy and light chains of IgG, and 
chain of IgM. Since all of them were also found in control exper-
iments without AAV particles (proteins that bind empty AVB
beads), these spots were not considered relevant for interaction
with AAV vectors. Identification of rAAV-6-associated hu-G3BP
was further confirmed by Western blot analysis (Fig. 1C and D).
Golden retriever muscular dystrophy (GRMD), the canine
model of Duchenne muscular dystrophy (DMD), is often used to
assess AAV-based therapy for DMD (4, 25). We tested whether the
G3BP of golden retrievers was also capable of interacting with
rAAV-6 similarly to its human homolog. Association of serum
proteins with purified rAAV-6 was tested in serum samples from
AAV-6 antibody-seronegative dogs by using either cosedimenta-
tion or coimmunoprecipitation methods followed by 2-D gel
analysis. Similar to what was observed in human sera, 2-D gels
exhibited multiple specific spots with an apparent molecular mass
of 85 kDa and a pI of 5.1 (Fig. 2A and B). These spots were also
identified as G3BP by MALDI-TOF analysis. The higher mobility
of dog G3BP than of hu-G3BP can be explained by the smaller size
of this protein (559 amino acids versus 585 in human) and also by
differences in glycosylation. Identification of rAAV-6-associated
dog G3BP was further confirmed by Western blot analysis (Fig. 2C
and D).
In view of the fact that the macaque is often considered a rele-
vant model in preclinical gene therapy studies, we tested whether
the G3BP of Macaca fascicularis origin (98% of identity with hu-
G3BP) interacts with rAAV-6 similarly to its human and dog ho-
mologs. Although the macaque G3BP was recognized by a poly-
clonal anti-hu-G3BP antibody, Western blot analysis of serum
samples investigated after immunoprecipitation with rAAV-6
showed, surprisingly, no detectable interaction with macaque
G3BP (Fig. 3A and B).
rAAV-6 does not interact with G3BP but with CRP in mouse
serum. Following similar experiments with mouse (C57BL/6) se-
FIG 3 Macaque G3BP does not interact with rAAV-6. Western blot analysis of
0.3 l of total serum from human and macaque demonstrated that macaque
G3BP is recognized by the anti-hu-G3BP antibody (A). Western blot analysis
with anti-G3BP antibody of proteins from macaque serum recovered via
rAAV-6 immobilized on AVB-Sepharose beads. Human serum on rAAV-6
beads was used as a positive control (B). (Top) Coomassie blue staining; (bot-
tom) corresponding Western blot analysis. Numbers to the left of each panel
are molecular weights (MW).
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rum, we did not detect spots corresponding to the murine protein
homolog of G3BP (i.e., the mouse cyclophilin C-associated pro-
tein, 68% homology to hu-G3BP, with an apparent molecular
mass of 77 kDa on SDS-PAGE and pI 5.0 [9, 14]) (Fig. 4A and B).
Instead of G3BP, protein immunoprecipitation experiments with
rAAV-6 readily detected a spot with a molecular mass of 24 kDa
(Fig. 4A and B). This spot was subsequently identified by MALDI-
TOF analysis as the mouse C-reactive protein (CRP). Retention of
the murine CRP by rAAV-6 was further confirmed by Western
blot analysis (Fig. 4C and D). Importantly, human CRP did not
react with rAAV-6 (Fig. 4E and F), thus demonstrating that this
AAV serotype interacted with serum proteins in a species-specific
manner.
Human G3BP interacts differentially with rAAV serotypes.
We further investigated interactions of several serotypes (rAAV-1,
-2, -5, -6, -7, -8, -9, and -10 and an rAAV-2/rAAV-8 chimera
named rAAV-2i8 [3]) with G3BP in the respective human anti-
body-seronegative sera. Immobilized on AVB-Sepharose
beads, rAAVs were incubated with relevant sera, and the result-
ing hu-G3BP binding was determined by Western blot analysis.
For rAAV-9, which does not bind AVB-Sepharose beads, puta-
tive complexes were assessed by cosedimentation. Noticeably,
hu-G3BP was recovered in the presence of rAAV-1, -5, and -6
but not in the presence of rAAV-2, -2i8, -7, -8, -9, and -10 (Fig.
5A and B). Binding affinities of rAAV-6 and -9 for hu-G3BP
were further analyzed by using surface plasmon resonance im-
agery (SPRi) (Fig. 5D). Again, rAAV-9 did not show any bind-
ing, while rAAV-6 displayed an association constant (KA) for
hu-G3BP of 10E9 M1.
Binding capacities of rAAV-1, -5, and -6 for hu-G3BP were
different. Three to five times less G3BP was bound by rAAV-1 or
rAAV-5 than by rAAV-6 (Fig. 5A). Interestingly, only six amino
acid residues differ between AAV-1 and AAV-6 VP1 proteins, sug-
gesting that an important molecular determinant for hu-G3BP
binding could lie within these amino acid residues. The K531 res-
idue is unique to AAV-6 among currently known serotypes, which
contain a conserved glutamate or aspartate residue at the corre-
sponding 531 position. We tested the significance of this residue in
hu-G3BP recovery by swapping amino acids at position 531 be-
tween rAAV-1 and rAAV-6. As shown in Fig. 5C, such modifica-
tions affected hu-G3BP binding: the rAAV-1(E531K) mutant in-
creased its hu-G3BP binding capacity nearly to the level of
rAAV-6, while rAAV-6(K531E) decreased to the level of rAAV-1.
These results confirmed that lysine 531 was a key determinant for
hu-G3BP binding. However, since this residue was previously
identified as a heparin-binding determinant on rAAV-6 capsids
FIG 4 CRP, but not G3BP, interacts with rAAV-6 in mouse serum. 2-DE of mouse serum proteins recovered with AVB-Sepharose immunoaffinity beads alone
(A) or with rAAV-6 (B). An additional protein of about 25 kDa was eluted from AVB-Sepharose in the presence of rAAV-6 and identified by MALDI-TOF
analysis as C-reactive protein (CRP). Identification of CRP was confirmed by Western blot analysis: Coomassie blue staining of SDS-PAGE gel (C) and
corresponding Western blot analysis using a goat anti-mouse polyclonal antibody (D). Lanes 1 and 2, protein extracts from mouse serum recovered via
rAAV-6/AVB-Sepharose or AVB-Sepharose alone, respectively. VP1, VP2, and VP3, as well as serum CRP (around 25 kDa in molecular mass), were detected in
lane 1. In lane 2, beads alone did not retain CRP, although some other unidentified proteins were recovered depending on washing stringency. The human
homolog of mouse CRP does not interact with rAAV-6 (Coomassie blue staining of SDS-PAGE gel [E] and corresponding Western blot analysis [F]). While
anti-human CRP antibodies were efficient at visualizing CRP in human serum, no such protein was recovered in the presence of rAAV-6 preadsorbed to
AVB-Sepharose. Lane 1, proteins recovered in the presence of rAAV-6 preadsorbed to AVB-Sepharose; lane 2, serum proteins retained by AVB-Sepharose beads
alone; lane 3, unfractionated human serum; lane 4, recombinant CRP (100 ng) stabilized with BSA. Numbers to the left of each panel are molecular masses in
kilodaltons.
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(51), we wondered whether binding to heparin and that to hu-
G3BP affected each other. Competition experiments with up to
100 g/ml of heparin (molar excess of 100 over G3BP) showed no
effect of heparin on hu-G3BP recovery by rAAV-6 (Fig. 6).
Human G3BP aggregates rAAV-6. Aggregation of rAAV-6 in
the presence of purified hu-G3BP was assessed by electron micros-
copy (EM). rAAV-6 was diluted until vector particles appeared as
individual units scattered over the grid (Fig. 7A). In the presence
of 1 g/ml hu-G3BP, small aggregates containing 15 to 200 vector
particles were observed (Fig. 7B). At 10 g/ml hu-G3BP, which
corresponds to the G3BP physiological concentration in human
blood (ranging from 1.3 to 17 g/ml), large electron-dense struc-
tures were formed (Fig. 6C). These structures were made of nu-
merous vector particles aggregated with hu-G3BP as evidenced by
anti-G3BP immunogold staining (data not shown). Consistent
with our binding assay data, rAAV-9 never formed such structures
in the presence of hu-G3BP (Fig. 7D, E, and F).
The propensity of vectors to aggregate with hu-G3BP was also
assessed by comparing vector recoveries in supernatant and pellet
fractions after low-speed centrifugation (Fig. 7G). According to
this experimental procedure, the respective rAAV was incubated
in 80 l of PBS or PBS containing 20 g/ml of hu-G3BP for 1 h,
and after centrifugation at 2,000  g for 10 min, the supernatant
(70 l) was carefully discarded. Ten-microliter aliquots from the
supernatant and precipitate were analyzed by SDS-PAGE. Vectors
were recovered equally in the two fractions in control samples
without hu-G3BP. In the presence of 20 g/ml hu-G3BP, rAAV-6
was preferentially found in the pellet fraction, while rAAV-9 was
FIG 5 Interaction of hu-G3BP with different serotypes of rAAV. (A) Interactions of human G3BP with different rAAV serotypes were assessed by SDS-PAGE and
Western blot analysis of serum proteins retained on rAAVs immobilized on AVB-Sepharose beads. (B) In the case of rAAV-9, interaction with hu-G3BP was
assessed by coprecipitation from serum by ultracentrifugation. (C) Interaction of rAAV mutants with hu-G3BP after swapping amino acids at position 531
between rAAV-1 and rAAV-6. MW, molecular weight standard. rAAV serotypes are designated above the lanes. Control beads, AVB-Sepharose beads without
rAAV; rec hu-G3BP, recombinant glycosylated human protein; recNG G3BP, recombinant nonglycosylated human protein. Positions of hu-G3BP and viral
capsid proteins are indicated by arrows. (D) Interactions of hu-G3BP with rAAV-6 and -9 were assessed by surface plasmon resonance imagery. rAAV vectors
were immobilized on glass prisms, and a dose-dependent binding study was performed using 10, 20, and 40 nM hu-G3BP.
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detected equally in the pellet fraction and the supernatant. In-
triguingly, rAAV-1 was not precipitated despite the fact that pre-
vious binding assays clearly showed that it could bind hu-G3BP.
Aggregation of rAAV-1(E531K) and rAAV-6(K531E) mutants
followed their capacities to bind hu-G3BP in vitro: the rAAV-1
mutant with Lys in position 531, which efficiently bound hu-
G3BP (Fig. 5), was precipitated by the protein, while rAAV-6 with
Glu in position 531, which bound hu-G3BP at a lower level, sim-
ilarly to rAAV-1 (Fig. 5), did not form aggregates precipitated at
low-speed centrifugation (Fig. 7).
In order to evaluate a ratio between rAAV-6 and hu-G3BP in
the aggregates, VP3 protein in precipitates was estimated after
Coomassie blue staining and hu-G3BP content was estimated by
Western blot analysis using known quantities of rAAV-6 and re-
combinant hu-G3BP as standards, respectively. Such quantifica-
tion allowed us to determine that each rAAV-6 particle could en-
gage two to six hu-G3BP monomers. Importantly, in human
serum per se G3BP was cosedimented with rAAV-6 under low-
speed centrifugation (Fig. 8).
Human G3BP hampers rAAV-6 recovery by immunoaffinity
beads. In order to confirm that the properties of rAAV-6 bound to
hu-G3BP are different from those of the free rAAV-6, we studied
whether hu-G3BP altered recognition of rAAV-6 by AVB-Sephar-
ose beads. For this goal, vectors were preincubated with either PBS
supplemented with BSA, human serum, or human serum de-
pleted of hu-G3BP by preincubation with immobilized anti-G3BP
antibodies. As expected, recovery of rAAV-6 under the PBS con-
dition was linearly proportional to the concentration of physical
vector particles (Fig. 9). In contrast, vector recovery in the pres-
ence of human serum was compromised and reduced by up to
1.3  10E12 physical particles/ml, although a gradual increase was
noted, similarly to the PBS condition, at high vector concentra-
tions. When serum was depleted of hu-G3BP, rAAV-6 recovery
was similar to that under the PBS condition. These results sug-
gested that hu-G3BP could either change vector surface properties
or disable the vector’s access to immunoaffinity beads by promot-
ing vector aggregation.
Human G3BP interaction with rAAV-6 impacts transduc-
tion efficacy in the mouse. To study the impact of hu-G3BP on
transduction efficiency in vivo, hu-G3BP and rAAV-6 antibody-
seronegative mice (C57BL/6) received intravenous injections of
rAAV-6 encoding the murine secreted embryonic alkaline phos-
phatase (MuSEAP) as a reporter gene, alone or preincubated with
purified hu-G3BP at 20 g/ml. Preincubated rAAV-6 samples
were less efficient than control rAAV-6, as illustrated by the
3-fold-lower level of MuSEAP in serum 2 weeks after injection
(296  87 ng/ml for rAAV-6/hu-G3BP versus 870  123 ng/ml for
rAAV-6 alone) (Fig. 10A).
To further address the effect of circulating hu-G3BP on rAAV-6
transduction efficiency, hu-G3BP was intravenously injected 1 min
prior to rAAV-6. By injecting 20 g of hu-G3BP, we estimated that
immediately after injection the peak of circulating hu-G3BP would be
about 13 g/ml, which is in the range of human physiological con-
centrations (ranging from 1.3 to 17 g/ml). The results showed that
hu-G3BP-preconditioned mice displayed a significant decrease in
MuSEAP levels (405  59 ng/ml) compared to that of mice injected
with rAAV-6 only (870  123 ng/ml).
On the opposite setting, when rAAV-6 (MuSEAP) was injected
before hu-G3BP (1-min interval), subsequent serum levels of
MuSEAP were not significantly different from those of controls
(842  271 versus 870  123 ng/ml, respectively), suggesting that
rAAV-6 might have already reached target organs ahead of the sec-
ondary injection of hu-G3BP and was eventually not accessible for
aggregation. Consistently, preincubation of rAAV-9 (MuSEAP)
with hu-G3BP had no impact on transduction efficiency as shown
by unchanged MuSEAP levels (Fig. 10B).
The efficacy of rAAV transduction in the presence of hu-G3BP
was also assessed using the intramuscular route of delivery. As
shown in Fig. 10C, preincubation of rAAV-6 with hu-G3BP re-
duced gene delivery to skeletal muscles more than 10-fold, while
the same procedure had no effect on vectors which did not bind
G3BP, rAAV-7 and rAAV-9. Intriguingly, transduction activity of
rAAV-1, which has a lower capacity for binding to G3BP than does
rAAV-6, was not affected by preincubation with hu-G3BP (Fig.
10C).
DISCUSSION
It is expected that clinical relevance for gene therapy in the context
of systemic muscle diseases would require widespread distribu-
tion of gene vectors in order to target the whole skeletal muscula-
ture and the heart; in this case, systemic delivery is likely the opti-
mal route of administration. Indeed, body-wide transduction
using particular rAAV serotypes (rAAV-1, -6, -8, and -9) has been
successfully achieved in rodents (11, 17, 45), and translating this
advance to the treatment of larger species such as dystrophic dogs
would definitely strengthen the rationale for this approach.
Transduction of large areas of muscle was achieved in mice by
using tail vein injections of rAAV-6 (17, 18, 46). In our hands, this
FIG 6 Heparin does not impact hu-G3BP binding to rAAV-6. rAAV-6 immo-
bilized on AVB beads was incubated with human serum in the presence of
increasing concentrations of heparin. Interactions of hu-G3BP with rAAV-6
were assessed by SDS-PAGE and Western blot analysis. (Top) Coomassie blue
staining of VP proteins of rAAV-6. (Bottom) Western blot analysis of hu-
G3BP bound to rAAV-6. M, molecular weight standard; lane 1, rAAV-6 im-
mobilized on AVB beads and incubated with human serum; lane 2, AVB-
Sepharose beads without rAAV incubated with human serum; lanes 3, 4, and 5,
rAAV-6 immobilized on AVB beads and incubated with human serum in the
presence of heparin at 1, 10, and 100 g/ml, respectively; lane 6, AVB beads
without rAAV incubated with human serum in the presence of 100 g/ml of
heparin. Hu-G3BP, 100 ng of recombinant glycosylated human G3BP.
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vector serotype was also efficient in dogs when we used locore-
gional limb vector delivery, whereby blood is removed prior to
vector infusion or by using percutaneous transendocardial deliv-
ery (4), but not after systemic injections. These findings prompted
us to investigate whether serum proteins, other than immuno-
globulins, could differentially react with rAAV-6 in these species.
A recent work has substantiated this hypothesis by showing that
depletion of immunoglobulins in dog serum removed their inhib-
itory effect on rAAV-1 and rAAV-2 transduction but not on
rAAV-6 transduction (40). Here, we show that two proteins of the
innate immune system, galectin 3 binding protein (G3BP) and
C-reactive protein (CRP), interact with different rAAV serotypes
in a species-specific manner.
G3BP is a highly glycosylated glycoprotein with all seven potential
N-glycosylation sites occupied by complex oligosaccharide chains
containing sialic acid (21) but not heparan sulfate (42). The mean
concentration of this protein in the plasma of normal children (n 
10) is 6.3 g/ml (19). Other studies carried out on 100 adults have
shown that normal concentrations range from 1.3 to 17 g/ml (en-
zyme immunoassay for the quantitative determination of s90K/Mac-
2BP in cell culture supernatant; human serum and plasma package
insert; IBL International GMBH, Hamburg, Germany; http:
//www.ibl-international.com/magento/media/catalog/product/B
/E/BE59271_IFU_en_s90_MAC-2BP_ELISA_V2011_04_sym2
.pdf). From a structural point of view, G3BP is composed of several
domains consisting of a single scavenger receptor cysteine-rich
(SRCR) domain at the N terminus, two central domains related to the
dimerization domains BTP/POZ and IVR of the Drosophila kelch
protein, and a C-terminal domain (21, 23, 31, 42). The evolutionarily
conserved SRCR domain is found in diverse transmembrane and
secreted glycoproteins, including CD5, CD6, M130, complement fac-
tor 1, and WC1 antigen (41). Many of these proteins are expressed by
cells involved in immunity (B cells, T cells, and macrophages) and are
implicated in host defense and immune regulation. G3BP interacts
with galectin 3 and other extracellular proteins such as collagens IV,
V, and VI; fibronectin; and nidogen. The protein forms linear and
ring-shaped oligomers. Investigations by scanning transmission elec-
tron microscopy have shown that G3BP rings present five to seven
14-nm-long segments made of two 92-kDa G3BP monomers. Al-
though rings vary in size, decamers of about 24 nm in diameter pre-
dominate. It is likely that the multivalency of G3BP provided by its
assembly into ring-like structures is of decisive importance for the
FIG 7 rAAV-6 forms aggregates with hu-G3BP. Formation of hu-G3BP/rAAV complexes was assessed by electron microscopy. (A to C) Aliquots of rAAV-6
(10E11 physical particles) were incubated in the presence of either 10 g/ml of BSA (A), BSA plus 1 g/ml of hu-G3BP (B), or BSA plus 10 g/ml of hu-G3BP
(C) for 1 h. Increasing the hu-G3BP concentration enhanced the formation of electron-dense aggregates. (D to F) Electron microscopy analysis of rAAV-9 (10E11
physical particles) in the presence of either 10 g/ml of BSA (D), BSA plus 1 g/ml of hu-G3BP (E), or BSA plus 10 g/ml of hu-G3BP (F). Including hu-G3BP
had no effect on the vector aggregation, thus indicating that complexation of hu-G3BP with rAAVs is serotype dependent. (G) Putative aggregate formation with
rAAV-6, rAAV-6(K531E), rAAV-1, rAAV-1(E531K), and rAAV-9 was assessed by low-speed centrifugation at 2,000  g for 10 min. Under such conditions,
aggregates are preferentially found in pellet (P) while free vectors are recovered in the supernatant (S). Repartition of rAAV in the two compartments was
estimated by Coomassie blue staining of viral proteins. Only rAAV-6 and rAAV-1(E531K) were precipitated under such conditions.
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linkage of different components and for an increase in binding activ-
ity (21, 31).
Estimation of rAAV-6 and hu-G3BP quantities in coprecipi-
tates suggests that each rAAV-6 particle could bind two to six
G3BP monomers. This ratio and the possibility of G3BP forming
ring-like structures compelled us to propose a 3-D network model
where many rAAV-6s are bridged with G3BP rings between them
(Fig. 11). Such a network structure could subsequently evolve into
large aggregates evidenced by EM and sedimentation analyses.
Importantly, 10 g/ml of hu-G3BP (7  1013 molecules) in
human blood is sufficient to react with 0.3  1013 rAAV parti-
cles/ml as illustrated by rAAV-6 precipitation after incubation
with normal human serum (Fig. 8). It is likely that such rAAV-6/
G3BP complexes would behave differently from free vectors in
crossing the barrier of blood vessels and would affect biodistribu-
tion. This hypothesis is in agreement with our in vivo results in
mice, where the presence of circulating hu-G3BP at physiological
levels in the human impacted rAAV-6 transduction, both when
administered systemically as a mixture and when administered
separately, with hu-G3BP being injected first. Intriguingly, when
hu-G3BP was injected only 1 min after rAAV-6, no significant
effect was noted on transduction levels, suggesting that either vec-
tor dilution in the bloodstream or binding to the vessel walls pre-
cluded vector aggregation by hu-G3BP. In contrast to the mouse
model, interaction with G3BP could be only one of the first steps
of vector recognition in humans, where G3BP is a natural ligand of
macrophage-secreted galectin 3, playing an important role in both
innate and adaptive immunity. Since ligand binding properties of
the human galectin 3 binding protein and its mouse homolog
cyclophilin C-associated protein are fairly different (24), the
mouse model could reflect only a part of the natural responses in
the homologous system.
Interestingly, rAAV-6, which provides whole-body gene trans-
fer in mouse models (18, 46), binds the mouse C-reactive protein
(CRP), one of the short pentraxins involved in host defense (1,
15). This protein promotes agglutination, bacterial capsular swell-
ing, phagocytosis, and complement fixation. The lack of efficiency
of CRP in blocking rAAV-6 tissue transduction might be due to
its low circulating levels in mice (43). Nevertheless, these levels
might vary from strain to strain or after stimulation (43) and
therefore provide a basis for explaining previously observed
variations in transduction efficacy between different mouse
models.
The nature of the interaction among different AAV serotypes
with hu-G3BP appears to vary significantly. Because vector clean-
liness is critical when assaying rAAV properties, we confirmed that
these differences were due to the vector serotypes by completing
binding assays on multiple brands of vectors made by different
laboratories using different methods of production (triple trans-
fection of 293 cells or the baculovirus/Sf9 system) and purified
either by density gradient or by AVB immunoaffinity. Impor-
tantly, the majority of in vitro rAAV/G3BP assays were performed
with rAAVs immobilized on AVB beads (except for rAAV-9),
which provided additional vector purification. Regardless of the
mode of vector production and purification, hu-G3BP–rAAV in-
teractions were highly reproducible, thus confirming that the in-
teractions that we describe here were true vector/host properties
and not the result of vector polishing peculiarities.
Interestingly, rAAV-6 formed large aggregates in the presence
of hu-G3BP, sedimenting at low speed, while rAAV-1, which dif-
FIG 8 Cosedimentation of rAAV-6 with hu-G3BP in human serum. rAAV-6
(2  10E12 pp) was incubated with 400 l of human serum in a 600-l total
volume for 1 h and then centrifuged at 2,000  g for 10 min. Supernatant (550
l) was discarded, and precipitate (50 l) was washed once with 550 l of PBS
and centrifuged at 2,000  g for 10 min. An 0.3-l amount of the first super-
natant and 3 l (from 50 l) of the last pellet were analyzed by SDS-PAGE
(top) and Western blot analysis (middle) against hu-G3BP or against VP pro-
teins (bottom). In the control experiment, serum was incubated with PBS. P,
precipitate; S, supernatant; rAAV-6, 1  1011 pp of rAAV-6; rec hu-G3BP,
recombinant glycosylated hu-G3BP.
FIG 9 Human G3BP hampers rAAV-6 recovery by AVB beads. Increasing
amounts of rAAV-6 (from 1  10E11 to 2  10E12 physical particles) were
incubated in a 600-l final volume for 1 h in the presence of either PBS sup-
plemented with 3% BSA, AAV-6-seronegative human serum, or the same se-
rum immunodepleted of G3BP by incubation with anti-G3BP antibodies
bound to magnetic beads. The amount of rAAV-6 recovered by AVB-Sephar-
ose was estimated by quantification of the VP3 protein after fractionation by
SDS-PAGE and Coomassie blue staining. In the presence of crude serum,
vector recovery was partially compromised, thus confirming the presence of an
interfering agent. Markedly, rAAV-6 recovery in the G3BP-depleted serum
was similar to the PBS condition, which displayed a linear relationship be-
tween load and recovery.
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fers from rAAV-6 by only six amino acids, did not show such a
phenomenon. Among these residues, the K531 residue, which is
known to play a role in heparin binding (32, 51), seems to be
crucial for the rAAV-6 –G3BP interaction. Nevertheless, depen-
dency on heparin is an unlikely determinant for hu-G3BP:
rAAV-2, which also binds heparin sulfate, does not interact with
hu-G3BP, and an excess of heparin does not compete with
rAAV-6 binding to hu-G3BP.
Taken together, our results demonstrate that rAAV vectors can
interact with serum proteins, other than immunoglobulins, in a
species-specific manner. We hypothesize that these interactions
could play a role in vector efficiency, and recent successes pertain-
ing to systemic gene therapy with rAAV-9 in dogs (25, 52) could
be attributed among other factors to the absence of interactions
between this vector and dog G3BP. These interactions could also
play a role in vector biodistribution, as was recently shown for
liver targeting with adenovirus serotype 5 through binding to co-
agulation factor X (48). Taking into account that these interac-
tions are truly species specific, this phenomenon should be taken
into consideration when studying vector distribution and efficacy
in different animal models as well as for toxicology studies.
FIG 11 Speculative model of putative interactions between hu-G3BP and
rAAV-6. Hu-G3BP makes high-molecular-weight ring structures (blue), po-
tentially bridging several rAAV particles (yellow). Accordingly, hu-G3BP
might form a scaffold for a “3D-net” involving a large number of sequestered
rAAV particles.
FIG 10 Human G3BP differentially attenuated transduction efficacies of rAAVs following either systemic or intramuscular delivery. (A) Intravenous
injections of rAAV-6 MuSEAP. From left to right, 6  10E11 vg of rAAV-6 in PBS, 6  10E11 vg of rAAV-6 preincubated with hu-G3BP (20 g/ml), 6 
10E11 vg of rAAV-6 in PBS followed by an injection of 20 g of hu-G3BP, and injection of 20 g of hu-G3BP followed by an injection of 6  10E11 vg
of rAAV-6. Transduction is expressed as the mean of MuSEAP serum levels (ng/ml)  standard deviation, 2 weeks after tail vein injection; at least three
mice were used for each condition. (B) Intravenous injections of rAAV-9 MuSEAP. (Left) Injection of 10E11 vg of rAAV-9 vectors in PBS; (right) vectors
mixed up with 20 g/ml hu-G3BP. (C) Intramuscular injections of rAAV-6 (5  10E9 vg), rAAV-1 (5  10E9 vg), rAAV-7 (5  10E9 vg), and rAAV-9
(1  10E9 vg) coding for MuSEAP. The respective vectors were injected alone or after preincubation with 20 g/ml hu-G3BP, and transduction was
expressed as the mean of MuSEAP serum levels (ng/ml) 2 weeks after injection. Three mice were used for each condition; data are representative of two
independent experiments.
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